<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Med (Lausanne)</journal-id><journal-id journal-id-type="iso-abbrev">Front Med (Lausanne)</journal-id><journal-id journal-id-type="publisher-id">Front. Med.</journal-id><journal-title-group><journal-title>Frontiers in Medicine</journal-title></journal-title-group><issn pub-type="epub">2296-858X</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC12098284</article-id><article-id pub-id-type="doi">10.3389/fmed.2025.1592621</article-id><article-categories><subj-group subj-group-type="heading"><subject>Medicine</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Gallbladder and biliary tract cancer burdens in China from 1990 to 2021 and projection to 2044: findings from the 2021 Global Burden of Disease study</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Jiang</surname><given-names>Zhongyi</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="fn0002" ref-type="author-notes">
<sup>&#x02020;</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/1564389/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Jiang</surname><given-names>Qianwei</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="fn0002" ref-type="author-notes">
<sup>&#x02020;</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/3050299/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Wang</surname><given-names>Pusen</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="c001" ref-type="corresp">
<sup>*</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/1526341/overview"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Zhong</surname><given-names>Lin</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="c001" ref-type="corresp">
<sup>*</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/908667/overview"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Department of General Surgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</institution>, <addr-line>Shanghai</addr-line>, <country>China</country></aff><aff id="aff2"><sup>2</sup><institution>Department of Liver Surgery and Organ Transplantation Center, Shenzhen Third People&#x02019;s Hospital, Second Affiliated Hospital, Southern University of Science and Technology</institution>, <addr-line>Shenzhen, Guangdong</addr-line>, <country>China</country></aff><aff id="aff3"><sup>3</sup><institution>Department of Gastric Surgery, Zhejiang Cancer Hospital</institution>, <addr-line>Hangzhou, Zhejiang</addr-line>, <country>China</country></aff><author-notes><fn fn-type="edited-by" id="fn0003"><p>Edited by: Qi Ling, Zhejiang University, China</p></fn><fn fn-type="edited-by" id="fn0004"><p>Reviewed by: Haoming Zhou, Nanjing Medical University, China</p><p>Di Lu, Zhejiang University, China</p></fn><corresp id="c001">*Correspondence: Pusen Wang, <email>pusenwang@foxmail.com</email>; Lin Zhong, <email>zhongl_3284@hotmail.com</email></corresp><fn fn-type="equal" id="fn0002"><p><sup>&#x02020;</sup>These authors have contributed equally to this work</p></fn></author-notes><pub-date pub-type="epub"><day>09</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>12</volume><elocation-id>1592621</elocation-id><history><date date-type="received"><day>12</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>28</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2025 Jiang, Jiang, Wang and Zhong.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Jiang, Jiang, Wang and Zhong</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><sec id="sec1"><title>Background</title><p>Gallbladder and biliary tract cancers (GBTCs) have high incidence and mortality rates in China, imposing a substantial disease burden. Establishing comprehensive strategies is crucial for alleviating this burden. We report the average estimated annual percentage change (EAPC) in age-standardized rates (ASRs) of GBTCs globally and in China via Global Burden of Disease (GBD) study 2021 data and the relationships of GBTCs with body mass index (BMI) and the sociodemographic index (SDI). The 2021&#x02013;2044 GBTCs prevalence trends were predicted by sex.</p></sec><sec id="sec2"><title>Methods</title><p>We collected and analyzed GBD data from 1990 to 2021, including incidence, prevalence, deaths, disability-adjusted life years (DALYs), and age-standardized incidence (ASIR), prevalence (ASPR), mortality (ASMR), and DALYs (ASDR) rates and calculated the proportion of deaths and DALYs attributable to risk factors by sex. Future trends from 2022 to 2044 were predicted with Nordpred age&#x02013;period&#x02013;cohort models.</p></sec><sec id="sec3"><title>Results</title><p>The number of GBTCs-related incident cases, prevalent cases, deaths, and DALYs increased from 1990 to 2021. However, the GBTCs-related ASMR and ASDR decreased during the same period. These changes may be related to risk factors, such as increased BMI. Furthermore, we used the projection model to estimate that the GBTCs-related ASPR in all populations will steadily increase, whereas the GBTCs-related ASMR and ASDR are expected to significantly decline until 2044.</p></sec><sec id="sec4"><title>Conclusion</title><p>The increasing GBTCs prevalence in China due to SDI advancements and population aging underscores the importance of early monitoring and prevention measures to alleviate the disease burden.</p></sec></abstract><kwd-group><kwd>gallbladder and biliary tract cancer</kwd><kwd>disease burden</kwd><kwd>epidemiology</kwd><kwd>ASR</kwd><kwd>EAPC</kwd></kwd-group><funding-group><funding-statement>The author(s) declare that financial support was received for the research and/or publication of this article. This work was supported by the National Key Research and Development Program of China (no. 2022YFC2304700), The Shenzhen High-level Hospital Construction Fund (XKJS-PWK-001), the National Natural Science Foundation of China (82302427), the Science and Technology Commission of Shanghai Municipality (23141902000), the Shenzhen Medical Research Fund (A2403056), and the Fundamental Research Funds for the Central Universities (YG2023QNA26).</funding-statement></funding-group><counts><fig-count count="4"/><table-count count="2"/><equation-count count="0"/><ref-count count="35"/><page-count count="8"/><word-count count="5234"/></counts><custom-meta-group><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Hepatobiliary Diseases</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec5"><title>Introduction</title><p>Gallbladder and biliary tract cancers (GBTCs) are a heterogeneous and aggressive group of adenocarcinomas characterized by high morbidity and mortality rates (<xref rid="ref1" ref-type="bibr">1</xref>, <xref rid="ref2" ref-type="bibr">2</xref>). Only a subset of patients with early-stage GBTCs can achieve a cure through surgical resection or liver transplantation (under stringent selection criteria); however, the majority of GBTC patients present with incurable locally advanced or metastatic disease due to delayed detection and thus have an exceedingly unfavorable prognosis, with only 2&#x02013;5% for 5-year overall survival (<xref rid="ref3" ref-type="bibr">3&#x02013;5</xref>). In 2020, there were 115,949 new cases and 84,695 new deaths from GBTCs worldwide, ranking 25th and 21st among the 36 cancers, respectively (<xref rid="ref6" ref-type="bibr">6</xref>). Despite accounting for only approximately 3% of all digestive system tumors, GBTC still imposes a significant societal and economic burden due to its unfavorable prognosis (<xref rid="ref7" ref-type="bibr">7</xref>).</p><p>The burden of disease evaluation currently serves as a comprehensive assessment system for quantifying the health impact of diseases and risk factors across diverse geographical regions, generations, age groups, and sexes. The distribution of GBTCs varies significantly globally, and the mortality rates of GBTCs have exhibited a downward trend in most countries worldwide. Certain high-income nations have experienced an upward trajectory in recent years (<xref rid="ref8" ref-type="bibr">8&#x02013;10</xref>). Moreover, previous studies have shown that the incidence and mortality rates of GBTCs are typically higher in Asia and South America than in high-income countries, such as China and Thailand, where the incidence is 40 times higher (<xref rid="ref1" ref-type="bibr">1</xref>, <xref rid="ref11" ref-type="bibr">11</xref>, <xref rid="ref12" ref-type="bibr">12</xref>). China poses a significant risk for GBTCs. According to the Global Burden of Diseases (GBD) 2019 study, China contributes to approximately one-fifth of the global disease burden in terms of new cases and deaths. Additionally, from 1990 to 2019, there has been a consistent upward trend in the age-standardized rates of incidence, prevalence, mortality, and DALYs for GBTCs in China (<xref rid="ref10" ref-type="bibr">10</xref>).</p><p>This study utilized comparable data extracted from the latest database of GBD 2021 Study to analyze the prevailing disease burden trends in GBTCs over three decades in China and project future disease burdens for the next two decades (<xref rid="ref13" ref-type="bibr">13</xref>). The findings will assist healthcare professionals and health organizations in comprehending the epidemiological shifts of GBTCs from a public health perspective, as well as the impact of changing lifestyles and preventive policies on recent trends and the current burden of GBTCs. These insights can further provide comprehensive analyses and forecasts for developing public health policies, prevention strategies, and treatment interventions.</p></sec><sec sec-type="methods" id="sec6"><title>Methods</title><sec id="sec7"><title>Data sources</title><p>The GBD 2021 is a publicly accessible database coordinated by the Institute for Health Metrics and Evaluation (IHME) that includes comprehensive data on mortality and disability in 204 countries and territories, including 288 causes of death, 371 diseases and injuries, and 88 risk factors worldwide. In this study, we extracted data on incidence, prevalence, mortality, disability-adjusted life-years (DALYs), and risk factors for GBTCs in China and globally across sex and age groups from 1990 to 2021 using the Results Tool of the GBD 2021.<xref rid="fn0001" ref-type="fn"><sup>1</sup></xref> The projected demographic data from a forecasting analysis for the GBD study by Vollset et al. (<xref rid="ref14" ref-type="bibr">14</xref>) were further used to forecast the age-standardized rates (ASRs) of GBTCs in both sexes from 2022 to 2044. The Socio-demographic Index (SDI) is a composite indicator of a country&#x02019;s lag-distributed income per capita, average years of schooling, and the fertility rate in females under the age of 25&#x0202f;years. The classification criteria for SDI are as follows: low SDI: 0.0000&#x02013;0.4658; low-middle SDI: 0. 4,658&#x02013;0.6188; middle SDI: 0.6188&#x02013;0.7120; high-middle SDI: 0.7120&#x02013;0.8103; high SDI: 0.8103&#x02013;1.0000. SDI values range from 0 to 1, with higher values indicating higher socioeconomic development (<xref rid="ref15" ref-type="bibr">15</xref>, <xref rid="ref16" ref-type="bibr">16</xref>).</p><p>In the present study, we used data from the GBD Study 2021, which was approved by the institutional review board of the University of Washington School of Medicine. As this is a secondary analysis of existing data, no additional human research ethics review or informed consent was needed. The original data collection obtained informed consent from the study participants or was granted exemptions by the institutional review board. Study data were anonymized and deidentified to protect the privacy and confidentiality of the study participants.</p></sec><sec id="sec8"><title>Statistical analysis</title><p>The estimated average percentage change (EAPC) was calculated to assess the trend of ASR for the burden of GBTCs, where the ASR trended upward if the EAPC value and the lower limit of the 95% confidence interval (CI) were greater than 0, downward if these values were less than 0, and constant when these values equaled 0. On the basis of the power5 age&#x02013;period&#x02013;cohort model, Nordpred age&#x02013;period&#x02013;cohort (NAPC) analysis was used to project the ASRs of incidence, prevalence, mortality, and DALYs for GBTCs by sex from 2021 to 2044 in China. The data analyses were conducted via R (version 4.4.1) and GraphPad Prism 9 software, whereas the &#x0201c;Nordpred (version 1.1)&#x0201d; package was used for the NAPC predictive model. <italic>p</italic>&#x0202f;&#x0003c;&#x0202f;0.05 was considered to indicate statistical significance.</p></sec></sec><sec sec-type="results" id="sec9"><title>Results</title><sec id="sec10"><title>Incidence and prevalence burdens of GBTCs in 2021</title><p>The incidence of GBTCs has significantly increased from 17.08 (&#x000d7;1,000) in 1990 to 51.72 (&#x000d7;1,000) in 2021 in China, with the ASIR increasing from 2.19 per 100,000 populations in 1990 to 2.49 per 100,000 populations in 2021 (<xref rid="tab1" ref-type="table">Table 1</xref>). The increase was more pronounced among males than females, with incident cases showing a remarkable 3.42-fold increase in males (EAPC&#x0202f;=&#x0202f;1.00; 95% CI&#x0202f;=&#x0202f;0.88 to 1.11) and a 2.68-fold increase in females (EAPC&#x0202f;=&#x0202f;&#x02212;0.04; 95% CI&#x0202f;=&#x0202f;&#x02212;0.14 to 0.06) (<xref rid="tab1" ref-type="table">Table 1</xref>; <xref rid="fig1" ref-type="fig">Figure 1A</xref>). The highest age-specific incidence rates (per 100,000 populations) for both males and females were consistently observed within the 90&#x02013;94-year-old age group (<xref rid="fig2" ref-type="fig">Figure 2A</xref>). Similarly, there has been a remarkable increase in the prevalence of GBTCs, with a significant increase from 17.98 (&#x000d7;1,000) in 1990 to 79.69 (&#x000d7;1,000) in 2021, accompanied by an increase in the age-standardized prevalence rate (ASPR) from 2.18 per 100,000 populations in 1990 to 3.77 per 100,000 populations in 2021 (<xref rid="tab1" ref-type="table">Table 1</xref>). The number of prevalent cases exhibited a significantly increased 5.10-fold among males (EAPC&#x0202f;=&#x0202f;2.62; 95% CI&#x0202f;=&#x0202f;2.42 to 2.83) and 3.80-fold among females (EAPC&#x0202f;=&#x0202f;1.35; 95% CI&#x0202f;=&#x0202f;1.21 to 1.50) (<xref rid="tab1" ref-type="table">Table 1</xref>; <xref rid="fig1" ref-type="fig">Figure 1B</xref>). In addition, the age-specific prevalence rate (per 100,000 populations) among males peaked in the 85&#x02013;89-year-old age group, whereas among females, it peaked in the 80&#x02013;84-year-old age group (<xref rid="fig2" ref-type="fig">Figure 2B</xref>).</p><table-wrap position="float" id="tab1"><label>Table 1</label><caption><p>Incidence and prevalence of GBTCs in 1990 and 2021 and their temporal trends from 1990 to 2021.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th align="center" valign="top" colspan="5" rowspan="1">Prevalence</th><th align="center" valign="top" colspan="5" rowspan="1">Incidence</th></tr><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th align="center" valign="top" colspan="2" rowspan="1">Numbers &#x000d7;1,000 (95% UI)</th><th align="center" valign="top" colspan="2" rowspan="1">ASR per 100,000 (95% UI)</th><th align="center" valign="top" rowspan="1" colspan="1">EAPC (95% CI)</th><th align="center" valign="top" colspan="2" rowspan="1">Numbers &#x000d7;1,000 (95% UI)</th><th align="center" valign="top" colspan="2" rowspan="1">ASR per 100,000 (95% UI)</th><th align="center" valign="top" rowspan="1" colspan="1">EAPC (95% CI)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Sex</td><td align="center" valign="top" rowspan="1" colspan="1">1990</td><td align="center" valign="top" rowspan="1" colspan="1">2021</td><td align="center" valign="top" rowspan="1" colspan="1">1990</td><td align="center" valign="top" rowspan="1" colspan="1">2021</td><td align="center" valign="top" rowspan="1" colspan="1">1990&#x02013;2021</td><td align="center" valign="top" rowspan="1" colspan="1">1990</td><td align="center" valign="top" rowspan="1" colspan="1">2021</td><td align="center" valign="top" rowspan="1" colspan="1">1990</td><td align="center" valign="top" rowspan="1" colspan="1">2021</td><td align="center" valign="top" rowspan="1" colspan="1">1990&#x02013;2021</td></tr><tr><td align="left" valign="middle" rowspan="3" colspan="1">China</td><td align="left" valign="middle" rowspan="1" colspan="1">Both</td><td align="center" valign="middle" rowspan="1" colspan="1">17.98 (13.59&#x02013;22.71)</td><td align="center" valign="middle" rowspan="1" colspan="1">79.69 (53.15&#x02013;103.93)</td><td align="center" valign="middle" rowspan="1" colspan="1">2.18 (1.66&#x02013;2.74)</td><td align="center" valign="middle" rowspan="1" colspan="1">3.77 (2.51&#x02013;4.91)</td><td align="center" valign="middle" rowspan="1" colspan="1">2.04 (1.86&#x02013;2.22)</td><td align="center" valign="middle" rowspan="1" colspan="1">17.08 (13.00&#x02013;21.74)</td><td align="center" valign="middle" rowspan="1" colspan="1">51.72 (35.62&#x02013;66.85)</td><td align="center" valign="middle" rowspan="1" colspan="1">2.19 (1.68&#x02013;2.79)</td><td align="center" valign="middle" rowspan="1" colspan="1">2.49 (1.71&#x02013;3.21)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.50 (0.40&#x02013;0.60)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Female</td><td align="center" valign="middle" rowspan="1" colspan="1">9.19 (6.28&#x02013;12.80)</td><td align="center" valign="middle" rowspan="1" colspan="1">34.89 (21.15&#x02013;47.65)</td><td align="center" valign="middle" rowspan="1" colspan="1">2.16 (1.48&#x02013;3.00)</td><td align="center" valign="middle" rowspan="1" colspan="1">3.15 (1.91&#x02013;4.30)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.35 (1.21&#x02013;1.50)</td><td align="center" valign="middle" rowspan="1" colspan="1">8.94 (6.15&#x02013;11.48)</td><td align="center" valign="middle" rowspan="1" colspan="1">23.92 (14.70&#x02013;32.56)</td><td align="center" valign="middle" rowspan="1" colspan="1">2.18 (1.51&#x02013;3.05)</td><td align="center" valign="middle" rowspan="1" colspan="1">2.16 (1.33&#x02013;2.95)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.04 (&#x02212;0.14&#x02013;0.06)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Male</td><td align="center" valign="middle" rowspan="1" colspan="1">8.79 (5.77&#x02013;12.29)</td><td align="center" valign="middle" rowspan="1" colspan="1">44.80 (25.71&#x02013;62.88)</td><td align="center" valign="middle" rowspan="1" colspan="1">2.22 (1.45&#x02013;3.16)</td><td align="center" valign="middle" rowspan="1" colspan="1">4.47 (2.58&#x02013;6.19)</td><td align="center" valign="middle" rowspan="1" colspan="1">2.62 (2.42&#x02013;2.83)</td><td align="center" valign="middle" rowspan="1" colspan="1">8.14 (5.38&#x02013;11.48)</td><td align="center" valign="middle" rowspan="1" colspan="1">27.80 (16.11&#x02013;38.97)</td><td align="center" valign="middle" rowspan="1" colspan="1">2.24 (1.46&#x02013;3.23)</td><td align="center" valign="middle" rowspan="1" colspan="1">2.89 (1.69&#x02013;3.40)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.00 (0.88&#x02013;1.11)</td></tr></tbody></table><table-wrap-foot><p>ASR, the age-standardized rate; EAPC, estimated average percentage change, CI, confidence interval; UI, uncertainty interval.</p></table-wrap-foot></table-wrap><fig position="float" id="fig1"><label>Figure 1</label><caption><p>Age-standardized incidence, prevalence, mortality, and DALYs rates of GBTCs in China from 1990 to 2021. <bold>(A)</bold> The ASIR of GBTCs. <bold>(B)</bold> The ASPR of GBTCs. <bold>(C)</bold> The ASMR of GBTCs. <bold>(D)</bold> The ASDR of GBTCs. ASIR, age-standardized incidence rate; ASPR, age-standardized prevalence rate; ASMR, age-standardized mortality rate; DALYs, disability-adjusted life years; ASDR, age-standardized DALYs rate; GBTCs, gallbladder and biliary tract cancers.</p></caption><graphic xlink:href="fmed-12-1592621-g001" position="float"/></fig><fig position="float" id="fig2"><label>Figure 2</label><caption><p>Age-specific incidence, prevalence, mortality, and DALYs rates of GBTCs by age and sex in China in 2021. <bold>(A)</bold> Age-specific incidence rate of GBTCs. <bold>(B)</bold> Age-specific prevalence rate of GBTCs. <bold>(C)</bold> Age-specific mortality rate of GBTCs. <bold>(D)</bold> Age-specific DALY rate of GBTCs. DALYs, disability-adjusted life years.</p></caption><graphic xlink:href="fmed-12-1592621-g002" position="float"/></fig></sec><sec id="sec11"><title>Deaths and DALYs burdens of GBTCs in 2021</title><p>The number of deaths and DALYs attributed to GBTCs exhibited an increasing trend in 2021, with 37.83 (&#x000d7; 1,000) deaths and 857.50 (&#x000d7; 1,000) DALYs recorded, respectively (<xref rid="tab2" ref-type="table">Table 2</xref>). In contrast, the ASMR and age-standardized DALYs rates in China declined from 1990 to 2021, with EAPCs of &#x02212;0.65 (95% CI&#x0202f;=&#x0202f;&#x02212;0.72 to &#x02212;0.58) and &#x02212;0.87 (95% CI&#x0202f;=&#x0202f;&#x02212;0.96 to &#x02212;0.78), respectively (<xref rid="tab2" ref-type="table">Table 2</xref>). Notably, during this period, the decline trajectories of the ASMR and the age-standardized DALYs rate were more pronounced among the female population than among the male population (<xref rid="tab2" ref-type="table">Table 2</xref>; <xref rid="fig1" ref-type="fig">Figures 1C</xref>,<xref rid="fig1" ref-type="fig">D</xref>). The highest age-specific mortality rate (per 100,000 populations) and DALYs rate for males consistently occurred in the 90&#x02013;94-year-old age group, as depicted in <xref rid="fig2" ref-type="fig">Figures 2C</xref>,<xref rid="fig2" ref-type="fig">D</xref>. Conversely, among females, the age-specific mortality rate (per 100,000 populations) reached its peak within the &#x0003e;95-year-old age group, whereas the age-specific DALYs rate (per 100,000 populations) peaked within the 75&#x02013;79-year-old age group.</p><table-wrap position="float" id="tab2"><label>Table 2</label><caption><p>Deaths and DALYs associated with GBTCs in 1990 and 2021 and their temporal trends from 1990 to 2021.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th align="center" valign="top" colspan="5" rowspan="1">Death</th><th align="center" valign="top" colspan="5" rowspan="1">DALYs</th></tr><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th align="center" valign="top" colspan="2" rowspan="1">Numbers &#x000d7;1,000 (95% UI)</th><th align="center" valign="top" colspan="2" rowspan="1">ASR per 100,000 (95% UI)</th><th align="center" valign="top" rowspan="1" colspan="1">EAPC (95% CI)</th><th align="center" valign="top" colspan="2" rowspan="1">Numbers &#x000d7;1,000 (95% UI)</th><th align="center" valign="top" colspan="2" rowspan="1">ASR per 100,000 (95% UI)</th><th align="center" valign="top" rowspan="1" colspan="1">EAPC (95% CI)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Sex</td><td align="center" valign="top" rowspan="1" colspan="1">1990</td><td align="center" valign="top" rowspan="1" colspan="1">2021</td><td align="center" valign="top" rowspan="1" colspan="1">1990</td><td align="center" valign="top" rowspan="1" colspan="1">2021</td><td align="center" valign="top" rowspan="1" colspan="1">1990&#x02013;2021</td><td align="center" valign="top" rowspan="1" colspan="1">1990</td><td align="center" valign="top" rowspan="1" colspan="1">2021</td><td align="center" valign="top" rowspan="1" colspan="1">1990</td><td align="center" valign="top" rowspan="1" colspan="1">2021</td><td align="center" valign="top" rowspan="1" colspan="1">1990&#x02013;2021</td></tr><tr><td align="left" valign="middle" rowspan="3" colspan="1">China</td><td align="left" valign="middle" rowspan="1" colspan="1">Both</td><td align="center" valign="middle" rowspan="1" colspan="1">17.25 (13.21&#x02013;22.14)</td><td align="center" valign="middle" rowspan="1" colspan="1">37.83 (26.65&#x02013;49.26)</td><td align="center" valign="middle" rowspan="1" colspan="1">2.32 (1.78&#x02013;2.97)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.85 (1.29&#x02013;2.40)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.65 (&#x02212;0.72 &#x02013; &#x02212;0.58)</td><td align="center" valign="middle" rowspan="1" colspan="1">452.35 (341.84&#x02013;581.40)</td><td align="center" valign="middle" rowspan="1" colspan="1">857.50 (601.93&#x02013;1121.11)</td><td align="center" valign="middle" rowspan="1" colspan="1">52.61 (39.99&#x02013;67.15)</td><td align="center" valign="middle" rowspan="1" colspan="1">40.38 (28.21&#x02013;52.61)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.87 (&#x02212;0.96 &#x02013; &#x02212;0.78)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Female</td><td align="center" valign="middle" rowspan="1" colspan="1">9.17 (6.35&#x02013;12.94)</td><td align="center" valign="middle" rowspan="1" colspan="1">18.31 (11.42&#x02013;24.76)</td><td align="center" valign="middle" rowspan="1" colspan="1">2.32 (1.60&#x02013;3.24)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.67 (1.04&#x02013;2.25)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;1.03 (&#x02212;1.11&#x02013;0.95)</td><td align="center" valign="middle" rowspan="1" colspan="1">230.96 (158.40&#x02013;322.84)</td><td align="center" valign="middle" rowspan="1" colspan="1">397.71 (248.64&#x02013;540.09)</td><td align="center" valign="middle" rowspan="1" colspan="1">52.85 (36.17&#x02013;73.76)</td><td align="center" valign="middle" rowspan="1" colspan="1">35.83 (22.37&#x02013;48.65)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;1.35 (&#x02212;1.47 &#x02013; &#x02212;1.25)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Male</td><td align="center" valign="middle" rowspan="1" colspan="1">8.08 (5.35&#x02013;11.61)</td><td align="center" valign="middle" rowspan="1" colspan="1">19.52 (11.62&#x02013;27.42)</td><td align="center" valign="middle" rowspan="1" colspan="1">2.38<break/>(1.55&#x02013;3.50)</td><td align="center" valign="middle" rowspan="1" colspan="1">2.11 (1.26&#x02013;2.92)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.25 (&#x02212;0.32 &#x02013; &#x02212;0.17)</td><td align="center" valign="middle" rowspan="1" colspan="1">221.39 (145.10&#x02013;311.19)</td><td align="center" valign="middle" rowspan="1" colspan="1">459.79 (269.77&#x02013;651.24)</td><td align="center" valign="middle" rowspan="1" colspan="1">52.86 (34.73&#x02013;75.74)</td><td align="center" valign="middle" rowspan="1" colspan="1">45.57 (26.80&#x02013;63.82)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.41 (&#x02212;0.51 &#x02013; &#x02212;0.31)</td></tr></tbody></table><table-wrap-foot><p>ASR, the age-standardized rate; EAPC, estimated average percentage change, CI, confidence interval; DALYs, disability-adjusted life years; UI, uncertainty interval.</p></table-wrap-foot></table-wrap></sec><sec id="sec12"><title>Risk factors for GBTCs</title><p>Previous GBD studies have consistently demonstrated that an elevated body mass index (BMI) (&#x0003e;23.0&#x0202f;kg/m<sup>2</sup>) is a significant and influential risk factor for both deaths and DALYs in GBTCs worldwide. In this study, we conducted a comprehensive analysis to compare the proportion of deaths and DALYs attributed to high BMI risk factors from 1990 to 2021, specifically within China. In 1990, the proportion of deaths attributed to the high-BMI risk factor was merely 5.3% for males and 6.1% for females in China, which higher than the proportions observed in low SDI and World Bank Low Income regions, but fell significantly below the global average (<xref rid="fig3" ref-type="fig">Figure 3A</xref>). However, in 2021, the proportions increased to 9.4% for males and 11.6% for females, representing 80 and 100% increases, respectively, and these data lower than those observed in regions characterized by high-middle SDI and World Bank Upper Middle Income regions as well as the global average (<xref rid="fig3" ref-type="fig">Figure 3B</xref>). A similar trend can be observed in the proportion of DALYs attributable to high BMI risk factors. For males, this proportion increased from 5.6% in 1990 to 10.0% in 2021, whereas for females, it rose from 6.3 to 12.2%, which also lower than the global average (<xref rid="fig3" ref-type="fig">Figures 3C</xref>,<xref rid="fig3" ref-type="fig">D</xref>).</p><fig position="float" id="fig3"><label>Figure 3</label><caption><p>The proportions of deaths and DALYs attributable to risk factors associated with GBTCs globally, in China, and in 9 regions in 1990 and 2021 by sex. <bold>(A)</bold> The proportion of deaths attributable to risk factors associated with the development of GBTCs in 1990. <bold>(B)</bold> The proportion of deaths attributable to risk factors for the development of GBTCs in 2021. <bold>(C)</bold> The proportion of DALYs attributable to risk factors for the development of GBTCs in 1990. <bold>(D)</bold> The proportion of DALYs attributable to risk factors for the development of GBTCs in 2021. DALYs, disability-adjusted life years; GBTCs, gallbladder and biliary tract cancers.</p></caption><graphic xlink:href="fmed-12-1592621-g003" position="float"/></fig></sec><sec id="sec13"><title>Predictions of GBTCs from 2022 to 2044</title><p>Using the NAPC model, we predicted the ASIRs of sex-specific GBTCs from 2022 to 2044. Our findings indicate a gradual decline in the ASIR for females during this period, whereas males are expected to experience an initial increase followed by a subsequent decrease, albeit with a smaller range of amplitude changes (<xref rid="fig4" ref-type="fig">Figure 4A</xref>). Furthermore, we anticipate a substantial increase in the ASPR for both males and females during this period, with a particularly pronounced increasing trend observed among males (<xref rid="fig4" ref-type="fig">Figure 4B</xref>). Notably, our predictions indicate a gradual and consistent decline in both ASMR rates and age-standardized DALYs rates attributed to GBTCs across all populations from 2022 to 2044 (<xref rid="fig4" ref-type="fig">Figures 4C,D</xref>).</p><fig position="float" id="fig4"><label>Figure 4</label><caption><p>Trends and predictions of the GBTCs disease burden in China from 1990 to 2044 by sex. The lines represent trends, and the columns represent numbers. <bold>(A)</bold> The ASIR and number of incident cases of GBTCs. <bold>(B)</bold> The ASPR and number of prevalent cases of GBTCs. <bold>(C)</bold> The ASMR and numbers of deaths associated with GBTCs. <bold>(D)</bold> The ASDR and number of DALYs associated with GBTCs. ASIR, age-standardized incidence rate; ASPR, age-standardized prevalence rate; ASMR, age-standardized mortality rate; DALYs, disability-adjusted life years; ASDR, age-standardized DALYs rate; GBTCs, gallbladder and biliary tract cancers.</p></caption><graphic xlink:href="fmed-12-1592621-g004" position="float"/></fig></sec></sec><sec sec-type="discussion" id="sec14"><title>Discussion</title><p>On the basis of data from the GBD 2021, in the present study, we present a comprehensive assessment of the current status in 2021, trends over the past 40&#x0202f;years, and predictions from 2022 to 2044 regarding the burden due to GBTCs in China. As evidenced by our findings, the number of incident cases, prevalent cases, deaths, and DALYs associated with GBTCs in China significantly increased by 3.03-fold, 4.43-fold, 2.19-fold, and 1.90-fold, respectively, from 1990 to 2021. Similarly, the ASIR and ASPR clearly exhibited a consistent upward trend over the 40-year period, whereas the ASMR and ASDR demonstrated a declining pattern. The forecast results from 2022 to 2024 suggest a potential upward trend in the GBTCs-related ASPR while indicating a downward trend in both the ASMR and ASDR. Furthermore, the overall change trend of the ASIR remains relatively stable at a high level. Although the disease burden of GBTCs varies significantly in terms of geographic region, country level, ethnicity, and culture, our findings align with those of previous studies indicating a progressively severe disease burden in East Asia and South Asia (<xref rid="ref7" ref-type="bibr">7</xref>, <xref rid="ref9" ref-type="bibr">9</xref>, <xref rid="ref17" ref-type="bibr">17</xref>).</p><p>Traditionally regarded as a rare tumor, GBTCs exhibit a remarkably high incidence in China, ranking second among hepatobiliary tumors following hepatocellular carcinoma (<xref rid="ref1" ref-type="bibr">1</xref>, <xref rid="ref17" ref-type="bibr">17</xref>). GBTCs account for approximately 15% of all hepatobiliary tumors in China (<xref rid="ref18" ref-type="bibr">18</xref>), although significant advancements in surgical techniques have resulted in cholecystectomy, hepatectomy and liver transplantation as curative treatments for GBTCs, several surgical limitations still exist, including tumor stage and primary site (<xref rid="ref19" ref-type="bibr">19</xref>, <xref rid="ref20" ref-type="bibr">20</xref>). Moreover, the potential adverse effects of surgery, such as ischemia&#x02013;reperfusion injury and infection, significantly impact patient prognosis (<xref rid="ref21" ref-type="bibr">21&#x02013;23</xref>). In the context of an increasingly aging population, GBTCs have emerged as a significant challenge to individuals&#x02019; well-being. Notably, the ASIR significantly increased for both males and females starting in 1998, with a pivotal turning point observed in 2005. Subsequently, the ASIR continued to demonstrate an upward trend among males but an overall downward trajectory among females. Furthermore, while both sexes exhibited a gradual increase in the ASPR, this trend was notably more pronounced among males. The disparities arise from biological factors (such as male-predominant visceral fat accumulation versus female subcutaneous fat distribution and estrogen protection), behavioral risks (including higher rates of smoking and alcohol use among males), and hormonal influences (such as the loss of estrogen&#x02019;s protective effects after menopause). These results highlight the necessity for gender-specific prevention strategies that target visceral fat reduction in men and promote metabolic health in postmenopausal women to reduce the risk of GBTCs (<xref rid="ref24" ref-type="bibr">24</xref>, <xref rid="ref25" ref-type="bibr">25</xref>). Despite metabolic, hormonal, and physical differences between males and females, the precise influence of sex on incidence and prevalence rates remains unclear due to significant regional disparities. For example, in East Asia and South Asia, there was a greater disease burden of GBTCs among males than among females, whereas the opposite trend was observed in Latin America (<xref rid="ref8" ref-type="bibr">8</xref>, <xref rid="ref9" ref-type="bibr">9</xref>, <xref rid="ref26" ref-type="bibr">26</xref>). The findings of our study also indicate a significantly elevated risk of both incidence and mortality from GBTCs among individuals aged 65&#x0202f;years and above, particularly within the 80&#x02013;94-year-old age group. The increased susceptibility of the elderly population to gallstones, due to factors such as reduced metabolic capacity and compromised immunity, increases their vulnerability to the development and fatality of GBTCs (<xref rid="ref10" ref-type="bibr">10</xref>, <xref rid="ref27" ref-type="bibr">27</xref>). Moreover, the rapid socioeconomic development in China has not only extended the life expectancy of its population but also given rise to the social issue of population aging, thereby exacerbating the disease burden of GBTCs. Therefore, it is imperative to prioritize disease prevention, early screening, and comprehensive care for the elderly population.</p><p>High BMI is now widely acknowledged as a significant risk factor for gastrointestinal tumors, including GBTCs (<xref rid="ref28" ref-type="bibr">28</xref>). With improvements in living conditions, however, certain lifestyle challenges, such as reduced physical activity and the consumption of high-calorie diets, have emerged. These factors have contributed to an overall increase in obesity rates within society (<xref rid="ref29" ref-type="bibr">29</xref>, <xref rid="ref30" ref-type="bibr">30</xref>). In 2021, China has transitioned from a country with low SDI and World Bank Low Income in 1990 to a country with high-middle SDI and World Bank Upper Middle Income. However, our study revealed a significant increase in the proportion of deaths and DALYs associated with high BMI in 2021 compared with 1990 in China, highlighting the escalating public health challenge posed by obesity and its consequences. Additionally, this phenomenon may be linked to a country&#x02019;s level of socioeconomic status. Although it has been suggested that the disease burden of GBTCs increases with SDI (<xref rid="ref9" ref-type="bibr">9</xref>, <xref rid="ref26" ref-type="bibr">26</xref>), current observations indicate a rapid increase in the disease burden of GBTCs within regions characterized by a lower SDI. Furthermore, gallstones are strongly related to GBTCs, and high BMI is an independent risk factor for gallstone development (<xref rid="ref31" ref-type="bibr">31</xref>, <xref rid="ref32" ref-type="bibr">32</xref>). Studies indicate a significant familial correlation between gallstones and biliary tract diseases. A family history of gallstones doubles the risk of GBTCs, while individuals with both gallstones and a positive family history face a 57-fold increased risk of GBTCs, suggesting a potential synergistic effect. These findings highlight the critical roles of genetic predisposition and high BMI in the pathogenesis of GBTCs (<xref rid="ref33" ref-type="bibr">33</xref>). On the one hand, the socioeconomic development of lower-SDI regions has facilitated advancements in medical care, leading to enhanced efficiency in GBTCs screening and diagnosis; on the other hand, the lifestyle and dietary habits of lower-SDI regions have gradually assimilated the high-burden dietary patterns prevalent in higher-SDI regions (<xref rid="ref34" ref-type="bibr">34</xref>, <xref rid="ref35" ref-type="bibr">35</xref>).</p><p>The disease burden of GBTCs in China is anticipated to escalate over the next two decades, necessitating the implementation of cost-effective strategies to address this substantial burden. The first step toward enhancing national awareness involves bolstering the dissemination of cancer prevention measures. To mitigate societal and individual burdens, proactive measures should be taken to promote healthy lifestyle behaviors, such as reducing BMI-related risk factors like smoking, unhealthy diets, obesity, and physical inactivity. Targeted interventions tailored for high-risk populations should include weight management programs, early screening initiatives, and lifestyle modifications. In light of the societal pressures stemming from an aging population, future research should prioritize advancing our understanding of GBTCs pathogenesis, with a particular emphasis on genetic and molecular biomarkers. Furthermore, it will be imperative to enhance prognosis by improving treatment technologies and diversifying therapeutic strategies.</p><p>The present study is subject to certain limitations. First, we exclusively utilized data from the GBD 2021, which may introduce some bias in terms of data accuracy and stability. Second, the current limited data analysis does not allow for further refinement of the analysis on the basis of subtypes derived from GBTCs. Additionally, in the present study, we considered only a limited number of risk factors, necessitating a broader exploration of potential risk factors associated with GBTCs. Finally, the prediction model should be regarded as a reference tool rather than an exact representation of future trends. Moving forward, we will further investigate the disease burden of GBTCs in clinical cohorts to provide more valuable insights for the formulation of public health prevention policies.</p></sec><sec sec-type="conclusions" id="sec15"><title>Conclusion</title><p>Our study provides a comprehensive chronological analysis of the disease burden trends of GBTCs in China over the past four decades as well as projections for the next two decades. Additionally, this study highlights sex and age-related disparities and underscores the importance of high BMI as a prominent risk factor for GBTCs. The results of this study provide robust data support for reducing the disease burden of GBTCs in the Chinese population, as well as formulating effective strategies and measures for their prevention and management.</p></sec></body><back><ack><p>We acknowledge the collaborators of the GBD Study 2021 for their invaluable contributions.</p></ack><fn-group><fn id="fn0001"><p>
<sup>1</sup>
<ext-link xlink:href="https://vizhub.healthdata.org/gbd-results/" ext-link-type="uri">https://vizhub.healthdata.org/gbd-results/</ext-link>
</p></fn></fn-group><sec sec-type="data-availability" id="sec16"><title>Data availability statement</title><p>The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.</p></sec><sec sec-type="author-contributions" id="sec17"><title>Author contributions</title><p>ZJ: Conceptualization, Data curation, Formal analysis, Validation, Writing &#x02013; original draft. QJ: Conceptualization, Data curation, Formal analysis, Validation, Writing &#x02013; original draft. PW: Supervision, Writing &#x02013; review &#x00026; editing. LZ: Funding acquisition, Supervision, Writing &#x02013; review &#x00026; editing.</p></sec><sec sec-type="COI-statement" id="sec19"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="ai-statement" id="sec20"><title>Generative AI statement</title><p>The authors declare that no Gen AI was used in the creation of this manuscript.</p></sec><sec sec-type="disclaimer" id="sec21"><title>Publisher&#x02019;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="ref1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valle</surname><given-names>JW</given-names></name><name><surname>Kelley</surname><given-names>RK</given-names></name><name><surname>Nervi</surname><given-names>B</given-names></name><name><surname>Oh</surname><given-names>D-Y</given-names></name><name><surname>Zhu</surname><given-names>AX</given-names></name></person-group>. <article-title>Biliary tract cancer</article-title>. <source>Lancet</source>. (<year>2021</year>) <volume>397</volume>:<fpage>428</fpage>&#x02013;<lpage>44</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0140-6736(21)00153-7</pub-id><pub-id pub-id-type="pmid">33516341</pub-id>
</mixed-citation></ref><ref id="ref2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamarca</surname><given-names>A</given-names></name><name><surname>Barriuso</surname><given-names>J</given-names></name><name><surname>McNamara</surname><given-names>MG</given-names></name><name><surname>Valle</surname><given-names>JW</given-names></name></person-group>. <article-title>Molecular targeted therapies: ready for "prime time" in biliary tract cancer</article-title>. <source>J Hepatol</source>. (<year>2020</year>) <volume>73</volume>:<fpage>170</fpage>&#x02013;<lpage>85</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jhep.2020.03.007</pub-id>, PMID: <pub-id pub-id-type="pmid">32171892</pub-id>
</mixed-citation></ref><ref id="ref3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harding</surname><given-names>JJ</given-names></name><name><surname>Khalil</surname><given-names>DN</given-names></name><name><surname>Fabris</surname><given-names>L</given-names></name><name><surname>Abou-Alfa</surname><given-names>GK</given-names></name></person-group>. <article-title>Rational development of combination therapies for biliary tract cancers</article-title>. <source>J Hepatol</source>. (<year>2023</year>) <volume>78</volume>:<fpage>217</fpage>&#x02013;<lpage>28</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jhep.2022.09.004</pub-id>, PMID: <pub-id pub-id-type="pmid">36150578</pub-id>
</mixed-citation></ref><ref id="ref4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>SA</given-names></name><name><surname>Thomas</surname><given-names>HC</given-names></name><name><surname>Davidson</surname><given-names>BR</given-names></name><name><surname>Taylor-Robinson</surname><given-names>SD</given-names></name></person-group>. <article-title>Cholangiocarcinoma</article-title>. <source>Lancet</source>. (<year>2005</year>) <volume>366</volume>:<fpage>1303</fpage>&#x02013;<lpage>14</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0140-6736(05)67530-7</pub-id> PMID: <pub-id pub-id-type="pmid">16214602</pub-id>
</mixed-citation></ref><ref id="ref5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>A</given-names></name><name><surname>Sharma</surname><given-names>KL</given-names></name><name><surname>Gupta</surname><given-names>A</given-names></name><name><surname>Yadav</surname><given-names>A</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name></person-group>. <article-title>Gallbladder cancer epidemiology, pathogenesis and molecular genetics: recent update</article-title>. <source>World J Gastroenterol</source>. (<year>2017</year>) <volume>23</volume>:<fpage>3978</fpage>&#x02013;<lpage>98</lpage>. doi: <pub-id pub-id-type="doi">10.3748/wjg.v23.i22.3978</pub-id>, PMID: <pub-id pub-id-type="pmid">28652652</pub-id>
</mixed-citation></ref><ref id="ref6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Miller</surname><given-names>KD</given-names></name><name><surname>Fuchs</surname><given-names>HE</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name></person-group>. <article-title>Cancer statistics, 2021</article-title>. <source>CA Cancer J Clin</source>. (<year>2021</year>) <volume>71</volume>:<fpage>21654</fpage>. doi: <pub-id pub-id-type="doi">10.3322/caac.21654</pub-id></mixed-citation></ref><ref id="ref7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>H-D</given-names></name><name><surname>Yu</surname><given-names>Y-W</given-names></name><name><surname>Li</surname><given-names>N</given-names></name><name><surname>Chen</surname><given-names>W-Q</given-names></name></person-group>. <article-title>Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020</article-title>. <source>Chin Med J</source>. (<year>2021</year>) <volume>134</volume>:<fpage>783</fpage>&#x02013;<lpage>91</lpage>. doi: <pub-id pub-id-type="doi">10.1097/CM9.0000000000001474</pub-id>, PMID: <pub-id pub-id-type="pmid">33734139</pub-id>
</mixed-citation></ref><ref id="ref8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torre</surname><given-names>LA</given-names></name><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Islami</surname><given-names>F</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name></person-group>. <article-title>Worldwide burden of and trends in mortality from gallbladder and other biliary tract cancers</article-title>. <source>Clin Gastroenterol Hepatol</source>. (<year>2018</year>) <volume>16</volume>:<fpage>427</fpage>&#x02013;<lpage>37</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cgh.2017.08.017</pub-id>, PMID: <pub-id pub-id-type="pmid">28826679</pub-id>
</mixed-citation></ref><ref id="ref9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>J</given-names></name><name><surname>Liang</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>X</given-names></name></person-group>. <article-title>Global, regional, and national burden and trends analysis of gallbladder and biliary tract cancer from 1990 to 2019 and predictions to 2030: a systematic analysis for the global burden of disease study 2019</article-title>. <source>Front Med</source>. (<year>2024</year>) <volume>11</volume>:<fpage>1384314</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fmed.2024.1384314</pub-id>, PMID: <pub-id pub-id-type="pmid">38638933</pub-id>
</mixed-citation></ref><ref id="ref10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Han</surname><given-names>K</given-names></name><name><surname>Song</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Current status, trends, and predictions in the burden of gallbladder and biliary tract cancer in China from 1990 to 2019</article-title>. <source>Chin Med J</source>. (<year>2022</year>) <volume>135</volume>:<fpage>1697</fpage>&#x02013;<lpage>706</lpage>. doi: <pub-id pub-id-type="doi">10.1097/CM9.0000000000002258</pub-id>, PMID: <pub-id pub-id-type="pmid">35984211</pub-id>
</mixed-citation></ref><ref id="ref11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>T</given-names></name></person-group>. <article-title>Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States</article-title>. <source>Hepatology</source>. (<year>2001</year>) <volume>33</volume>:<fpage>1353</fpage>&#x02013;<lpage>7</lpage>. doi: <pub-id pub-id-type="doi">10.1053/jhep.2001.25087</pub-id><pub-id pub-id-type="pmid">11391522</pub-id>
</mixed-citation></ref><ref id="ref12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sripa</surname><given-names>B</given-names></name><name><surname>Kaewkes</surname><given-names>S</given-names></name><name><surname>Sithithaworn</surname><given-names>P</given-names></name><name><surname>Mairiang</surname><given-names>E</given-names></name><name><surname>Laha</surname><given-names>T</given-names></name><name><surname>Smout</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Liver fluke induces cholangiocarcinoma</article-title>. <source>PLoS Med</source>. (<year>2007</year>) <volume>4</volume>:<fpage>e201</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pmed.0040201</pub-id>, PMID: <pub-id pub-id-type="pmid">17622191</pub-id>
</mixed-citation></ref><ref id="ref13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab id="coll1">GBD 2021 Diabetes Collaborators</collab></person-group>. <article-title>Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the global burden of disease study 2021</article-title>. <source>Lancet</source>. (<year>2023</year>) <volume>402</volume>:<fpage>203</fpage>&#x02013;<lpage>34</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0140-6736(23)01301-6</pub-id>, PMID: <pub-id pub-id-type="pmid">37356446</pub-id>
</mixed-citation></ref><ref id="ref14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vollset</surname><given-names>SE</given-names></name><name><surname>Goren</surname><given-names>E</given-names></name><name><surname>Yuan</surname><given-names>C-W</given-names></name><name><surname>Cao</surname><given-names>J</given-names></name><name><surname>Smith</surname><given-names>AE</given-names></name><name><surname>Hsiao</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Fertility, mortality, migration, and population scenarios for 195 countries and territories from 2017 to 2100: a forecasting analysis for the global burden of disease study</article-title>. <source>Lancet</source>. (<year>2020</year>) <volume>396</volume>:<fpage>1285</fpage>&#x02013;<lpage>306</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0140-6736(20)30677-2</pub-id>, PMID: <pub-id pub-id-type="pmid">32679112</pub-id>
</mixed-citation></ref><ref id="ref15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>Q</given-names></name><name><surname>Shu</surname><given-names>Y</given-names></name><name><surname>Jiang</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Pan</surname><given-names>S</given-names></name><name><surname>Jiang</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Burdens of stomach and esophageal cancer from 1990 to 2019 and projection to 2030 in China: findings from the 2019 global burden of disease study</article-title>. <source>J Glob Health</source>. (<year>2024</year>) <volume>14</volume>:<fpage>04025</fpage>. doi: <pub-id pub-id-type="doi">10.7189/jogh.14.04025</pub-id>, PMID: <pub-id pub-id-type="pmid">38180951</pub-id>
</mixed-citation></ref><ref id="ref16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bai</surname><given-names>Z</given-names></name><name><surname>Han</surname><given-names>J</given-names></name><name><surname>An</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Du</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>The global, regional, and national patterns of change in the burden of congenital birth defects, 1990-2021: an analysis of the global burden of disease study 2021 and forecast to 2040</article-title>. <source>EClinicalMedicine</source>. (<year>2024</year>) <volume>77</volume>:<fpage>102873</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.eclinm.2024.102873</pub-id>, PMID: <pub-id pub-id-type="pmid">39416384</pub-id>
</mixed-citation></ref><ref id="ref17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banales</surname><given-names>JM</given-names></name><name><surname>Marin</surname><given-names>JJG</given-names></name><name><surname>Lamarca</surname><given-names>A</given-names></name><name><surname>Rodrigues</surname><given-names>PM</given-names></name><name><surname>Khan</surname><given-names>SA</given-names></name><name><surname>Roberts</surname><given-names>LR</given-names></name><etal/></person-group>. <article-title>Cholangiocarcinoma 2020: the next horizon in mechanisms and management</article-title>. <source>Nat Rev Gastroenterol Hepatol</source>. (<year>2020</year>) <volume>17</volume>:<fpage>557</fpage>&#x02013;<lpage>88</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41575-020-0310-z</pub-id>, PMID: <pub-id pub-id-type="pmid">32606456</pub-id>
</mixed-citation></ref><ref id="ref18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>Z-G</given-names></name><name><surname>Zeng</surname><given-names>T-M</given-names></name><name><surname>Tao</surname><given-names>C-J</given-names></name></person-group>. <article-title>Current and emerging immunotherapeutic approaches for biliary tract cancers</article-title>. <source>Hepatobil Pancreat Dis Int</source>. (<year>2022</year>) <volume>21</volume>:<fpage>440</fpage>&#x02013;<lpage>9</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.hbpd.2022.08.015</pub-id>, PMID: <pub-id pub-id-type="pmid">36115807</pub-id>
</mixed-citation></ref><ref id="ref19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazzaferro</surname><given-names>V</given-names></name><name><surname>Gorgen</surname><given-names>A</given-names></name><name><surname>Roayaie</surname><given-names>S</given-names></name><name><surname>Busset</surname><given-names>MDD</given-names></name><name><surname>Sapisochin</surname><given-names>G</given-names></name></person-group>. <article-title>Liver resection and transplantation for intrahepatic cholangiocarcinoma</article-title>. <source>J Hepatol</source>. (<year>2020</year>) <volume>72</volume>:<fpage>364</fpage>&#x02013;<lpage>77</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jhep.2019.11.020</pub-id><pub-id pub-id-type="pmid">31954498</pub-id>
</mixed-citation></ref><ref id="ref20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gunasekaran</surname><given-names>G</given-names></name><name><surname>Bekki</surname><given-names>Y</given-names></name><name><surname>Lourdusamy</surname><given-names>V</given-names></name><name><surname>Schwartz</surname><given-names>M</given-names></name></person-group>. <article-title>Surgical treatments of hepatobiliary cancers</article-title>. <source>Hepatology</source>. (<year>2021</year>) <volume>73</volume>:<fpage>128</fpage>&#x02013;<lpage>36</lpage>. doi: <pub-id pub-id-type="doi">10.1002/hep.31325</pub-id><pub-id pub-id-type="pmid">32438491</pub-id>
</mixed-citation></ref><ref id="ref21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maspero</surname><given-names>M</given-names></name><name><surname>Yilmaz</surname><given-names>S</given-names></name><name><surname>Cazzaniga</surname><given-names>B</given-names></name><name><surname>Raj</surname><given-names>R</given-names></name><name><surname>Ali</surname><given-names>K</given-names></name><name><surname>Mazzaferro</surname><given-names>V</given-names></name><etal/></person-group>. <article-title>The role of ischaemia-reperfusion injury and liver regeneration in hepatic tumour recurrence</article-title>. <source>JHEP Rep Innov Hepatol</source>. (<year>2023</year>) <volume>5</volume>:<fpage>100846</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jhepr.2023.100846</pub-id>, PMID: <pub-id pub-id-type="pmid">37771368</pub-id>
</mixed-citation></ref><ref id="ref22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hellinger</surname><given-names>WC</given-names></name><name><surname>Crook</surname><given-names>JE</given-names></name><name><surname>Heckman</surname><given-names>MG</given-names></name><name><surname>Diehl</surname><given-names>NN</given-names></name><name><surname>Shalev</surname><given-names>JA</given-names></name><name><surname>Zubair</surname><given-names>AC</given-names></name><etal/></person-group>. <article-title>Surgical site infection after liver transplantation: risk factors and association with graft loss or death</article-title>. <source>Transplantation</source>. (<year>2009</year>) <volume>87</volume>:<fpage>1387</fpage>&#x02013;<lpage>93</lpage>. doi: <pub-id pub-id-type="doi">10.1097/TP.0b013e3181a25133</pub-id><pub-id pub-id-type="pmid">19424041</pub-id>
</mixed-citation></ref><ref id="ref23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jadlowiec</surname><given-names>CC</given-names></name><name><surname>Taner</surname><given-names>T</given-names></name></person-group>. <article-title>Liver transplantation: current status and challenges</article-title>. <source>World J Gastroenterol</source>. (<year>2016</year>) <volume>22</volume>:<fpage>4438</fpage>&#x02013;<lpage>45</lpage>. doi: <pub-id pub-id-type="doi">10.3748/wjg.v22.i18.4438</pub-id>, PMID: <pub-id pub-id-type="pmid">27182155</pub-id>
</mixed-citation></ref><ref id="ref24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhan</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Guo</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>Impact of high body mass index on gallbladder and biliary tract cancer burden in China: a comprehensive analysis of trends from 1990 to 2021</article-title>. <source>World J Surg Oncol</source>. (<year>2024</year>) <volume>22</volume>:<fpage>296</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12957-024-03582-4</pub-id>, PMID: <pub-id pub-id-type="pmid">39529095</pub-id>
</mixed-citation></ref><ref id="ref25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pilgrim</surname><given-names>CHC</given-names></name><name><surname>Groeschl</surname><given-names>RT</given-names></name><name><surname>Christians</surname><given-names>KK</given-names></name><name><surname>Gamblin</surname><given-names>TC</given-names></name></person-group>. <article-title>Modern perspectives on factors predisposing to the development of gallbladder cancer</article-title>. <source>HPB</source>. (<year>2013</year>) <volume>15</volume>:<fpage>839</fpage>&#x02013;<lpage>44</lpage>. doi: <pub-id pub-id-type="doi">10.1111/hpb.12046</pub-id>, PMID: <pub-id pub-id-type="pmid">23458506</pub-id>
</mixed-citation></ref><ref id="ref26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ouyang</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Lu</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>The global, regional, and national burden of gallbladder and biliary tract cancer and its attributable risk factors in 195 countries and territories, 1990 to 2017: a systematic analysis for the global burden of disease study 2017</article-title>. <source>Cancer</source>. (<year>2021</year>) <volume>127</volume>:<fpage>2238</fpage>&#x02013;<lpage>50</lpage>. doi: <pub-id pub-id-type="doi">10.1002/cncr.33476</pub-id>, PMID: <pub-id pub-id-type="pmid">33748947</pub-id>
</mixed-citation></ref><ref id="ref27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pang</surname><given-names>Y</given-names></name><name><surname>Lv</surname><given-names>J</given-names></name><name><surname>Kartsonaki</surname><given-names>C</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Causal effects of gallstone disease on risk of gastrointestinal cancer in Chinese</article-title>. <source>Br J Cancer</source>. (<year>2021</year>) <volume>124</volume>:<fpage>1864</fpage>&#x02013;<lpage>72</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41416-021-01325-w</pub-id>, PMID: <pub-id pub-id-type="pmid">33772150</pub-id>
</mixed-citation></ref><ref id="ref28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lauby-Secretan</surname><given-names>B</given-names></name><name><surname>Scoccianti</surname><given-names>C</given-names></name><name><surname>Loomis</surname><given-names>D</given-names></name><name><surname>Grosse</surname><given-names>Y</given-names></name><name><surname>Bianchini</surname><given-names>F</given-names></name><name><surname>Straif</surname><given-names>K</given-names></name></person-group>. <article-title>Body fatness and Cancer--viewpoint of the IARC working group</article-title>. <source>N Engl J Med</source>. (<year>2016</year>) <volume>375</volume>:<fpage>794</fpage>&#x02013;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJMsr1606602</pub-id>, PMID: <pub-id pub-id-type="pmid">27557308</pub-id>
</mixed-citation></ref><ref id="ref29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hemmingsson</surname><given-names>E</given-names></name></person-group>. <article-title>The unparalleled rise of obesity in China: a call to action</article-title>. <source>Int J Obes</source>. (<year>2005</year>) <volume>45</volume>:<fpage>921</fpage>&#x02013;<lpage>2</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41366-021-00774-w</pub-id></mixed-citation></ref><ref id="ref30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>F</given-names></name></person-group>. <article-title>Physical activity and health in the presence of China's economic growth: meeting the public health challenges of the aging population</article-title>. <source>J Sport Health Sci</source>. (<year>2016</year>) <volume>5</volume>:<fpage>258</fpage>&#x02013;<lpage>69</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jshs.2016.06.004</pub-id>, PMID: <pub-id pub-id-type="pmid">30356539</pub-id>
</mixed-citation></ref><ref id="ref31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>L</given-names></name><name><surname>Aili</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Saiding</surname><given-names>A</given-names></name><name><surname>Abudureyimu</surname><given-names>K</given-names></name></person-group>. <article-title>Prevalence of and risk factors for gallstones in Uighur and Han Chinese</article-title>. <source>World J Gastroenterol</source>. (<year>2014</year>) <volume>20</volume>:<fpage>14942</fpage>&#x02013;<lpage>9</lpage>. doi: <pub-id pub-id-type="doi">10.3748/wjg.v20.i40.14942</pub-id>, PMID: <pub-id pub-id-type="pmid">25356055</pub-id>
</mixed-citation></ref><ref id="ref32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aune</surname><given-names>D</given-names></name><name><surname>Norat</surname><given-names>T</given-names></name><name><surname>Vatten</surname><given-names>LJ</given-names></name></person-group>. <article-title>Body mass index, abdominal fatness and the risk of gallbladder disease</article-title>. <source>Eur J Epidemiol</source>. (<year>2015</year>) <volume>30</volume>:<fpage>1009</fpage>&#x02013;<lpage>19</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s10654-015-0081-y</pub-id><pub-id pub-id-type="pmid">26374741</pub-id>
</mixed-citation></ref><ref id="ref33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsing</surname><given-names>AW</given-names></name><name><surname>Bai</surname><given-names>Y</given-names></name><name><surname>Andreotti</surname><given-names>G</given-names></name><name><surname>Rashid</surname><given-names>A</given-names></name><name><surname>Deng</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Family history of gallstones and the risk of biliary tract cancer and gallstones: a population-based study in Shanghai, China</article-title>. <source>Int J Cancer</source>. (<year>2007</year>) <volume>121</volume>:<fpage>832</fpage>&#x02013;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.1002/ijc.22756</pub-id> PMID: <pub-id pub-id-type="pmid">17450525</pub-id>
</mixed-citation></ref><ref id="ref34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kopp</surname><given-names>W</given-names></name></person-group>. <article-title>How Western diet and lifestyle drive the pandemic of obesity and civilization diseases</article-title>. <source>Diabetes Metab Syndr Obes</source>. (<year>2019</year>) <volume>12</volume>:<fpage>2221</fpage>&#x02013;<lpage>36</lpage>. doi: <pub-id pub-id-type="doi">10.2147/DMSO.S216791</pub-id>, PMID: <pub-id pub-id-type="pmid">31695465</pub-id>
</mixed-citation></ref><ref id="ref35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>D-T</given-names></name><name><surname>Singh</surname><given-names>V</given-names></name></person-group>. <article-title>Obesity and hypertension in Asia: current status and challenges</article-title>. <source>Lancet Reg Health West Pac</source>. (<year>2021</year>) <volume>15</volume>:<fpage>100243</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.lanwpc.2021.100243</pub-id><pub-id pub-id-type="pmid">34528017</pub-id>
</mixed-citation></ref></ref-list></back></article>